Clinical Trials Browser

Completed × INDUSTRY × lazertinib × Clear all

NCT05862194 2023-08-22

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Carcinoma, Non-Small-Cell Lung